©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Nov 14, 2015; 21(42): 12101-12113
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12101
Published online Nov 14, 2015. doi: 10.3748/wjg.v21.i42.12101
Hepatitis C virus infection: Are there still specific problems with genotype 3?
Claire Gondeau, Georges Philippe Pageaux, Dominique Larrey, Department of Hepato-gastroenterology A, Hospital Saint Eloi, CHRU, 34295 Montpellier, France
Claire Gondeau, Dominique Larrey, INSERM U1183, Institute of Regenerative Medicine and Biotherapy, University of Montpellier, 34295 Montpellier, France
Author contributions: Gondeau C conducted the review of existing research and drafted the manuscript; Pageaux GP and Larrey D edited the final version.
Supported by Agence Nationale de la Recherche sur le SIDA et les Hépatites Virales.
Conflict-of-interest statement: Gondeau C declare no conflict of interest; Pageaux GP and Larrey D have received fees for serving as speakers and advisory board members for BMS, Gilead, Merck, Janssen. Larrey D has received fees for serving as a speaker and advisory board member for Abbvie.
Correspondence to: Claire Gondeau, PhD, INSERM U1183, Institute of Regenerative Medicine and Biotherapy, University of Montpellier, 34295 Montpellier, France. claire.gondeau@inserm.fr
Telephone: +33-4-67330493 Fax: +33-4-67330459
Received: June 29, 2015
Peer-review started: July 3, 2015
First decision: July 20, 2015
Revised: August 7, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 14, 2015
Processing time: 135 Days and 9.5 Hours
Peer-review started: July 3, 2015
First decision: July 20, 2015
Revised: August 7, 2015
Accepted: September 30, 2015
Article in press: September 30, 2015
Published online: November 14, 2015
Processing time: 135 Days and 9.5 Hours
Core Tip
Core tip: This article reviews the complex relationship between hepatitis C virus (HCV) genotypes and the possible complications in chronically infected patients. We discuss recent updates on the epidemiology and clinical aspects of HCV genotype 3 infection, including the currently available therapies. We also describe model systems to study the HCV genotype-specific molecular mechanisms.